Contrast Media & Molecular Imaging / 2018 / Article / Tab 2

Research Article

Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms

Table 2

Sensitivity and uptake of 68Ga-DOTATATE and 18F-FDG PET/CT for different primary sites and grades.

Sensitivity (%) (mean ± SD)
68Ga-DOTATATE18F-FDG PET/CT68Ga-DOTATATE18F-FDG PET/CT

Primary lesion
 Gastrointestinal tract55.8%74.4%16.75 ± 2.627.56 ± 0.87
 Pancreas85.2%66.7%29.87 ± 4.776.51 ± 0.78
WD NET80.4%58.8%28.87 ± 3.524.51 ± 0.45
 Gastrointestinal NET75.0%54.2%22.68 ± 2.773.71 ± 0.45
 Pancreatic NET89.5%52.6%31.19 ± 4.255.13 ± 0.93
PD NEC37.5%100.0%10.86 ± 1.7811.46 ± 0.75
 Gastrointestinal NEC31.6%100.0%9.26 ± 1.2512.44 ± 1.11
 Pancreatic NEC75.0%100.0%18.23 ± 5.9310.23 ± 0.67

WD, well-differentiated; PD, poorly differentiated; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma.